Ribociclib (Kisqali) and fulvestrant for advanced HR positive, HER2‐negative breast cancer in postmenopausal women, first or second line

featured image
Indications: Breast cancer
Therapeutic Areas: Breast Cancer
Year: 2017

Breast cancer is the most common cancer in the UK. Most women who get breast cancer are over 50 years of age. However, younger women, and in rare cases, men, may also get it. Survival beyond five years from diagnosis is relatively high but it depends on cancer stage at diagnosis, with less chance of survival at advanced stages.
There are many types of breast cancer. Ribociclib is a new treatment for a type of breast cancer that is called hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative. Ribociclib it is taken orally and works by stopping cancer cells multiplying. If taken in combination with an intramuscular injection of fulvestrant, which stops the effect of hormones altering the breast cells, ribociclib has the potential to prolong survival free progression. If licenced, this combination of treatments will offer an additional therapy choice for those patients newly diagnosed with HR+/HER2 –ve, or a second-line option for those who have already had hormonal therapy but their cancer has relapsed.